AHKSF
Asahi Kasei Corporation
Set alert
- YTD
- +17.02%
- 1 year
- +29.86%
- Open
- 10.35
- Prev close
- 10.42
- Mkt cap
- 13.89B
- Vol
- 100
- Avg vol
- 503
- EPS
- 0.92
- P/E
- 11.32
More statistics
- Low
- 10.35
- High
- 10.35
- Earnings
- Nov 11, 2026
News
3 weeks ago businesswire.com
Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults
TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolina,…
3 weeks ago reuters.com
US FDA approves Asahi Kasei's drug for persistent herpes infections
The US FDA on Friday approved Japan's Asahi Kasei's drug for persistent herpes simplex virus sores in certain patients with weakened immune systems who have not responded to available antiviral…
3 weeks ago businesswire.com
Asahi Kasei Microdevices Holds IEEE Milestone Commemoration Ceremony in Nobeoka for the Commercialization of Thin-Film Hall Elements
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices held a ceremony to celebrate the recognition of the 1983 commercialization of thin-film Hall elements as an IEEE Milestone.
3 weeks ago businesswire.com
Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients
TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics announced that the first patient has been dosed in a randomized Phase 2a clinical trial (NCT07503561) evaluating AIC468.
1 month ago businesswire.com
Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics
TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Veloxis Pharmaceuticals, Calliditas Therapeutics, and AiCuris will come together under the Asahi Kasei Therapeutics brand.
1 month ago businesswire.com
Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing
GLENVIEW, Ill.--(BUSINESS WIRE)--Asahi Kasei Bioprocess will unveil the VANTIJ® SU-VFC Benchtop at Bioprocess International East (BPI EAST) 2026.
1 month ago businesswire.com
Asahi Kasei Microdevices' CZ39 and CZ3K Current Sensors Featured in Microchip Technology's Machine Learning-Based Arc Fault Detection Reference Design
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices has announced that its CZ39 and CZ3K series have been adopted as in Microchip Technology's ML/AI-based AFD reference design.
2 months ago businesswire.com
Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy
TOKYO--(BUSINESS WIRE)--Asahi Kasei held a grand opening ceremony for its new Hipore™ wet-process lithium-ion battery separator coating line in Charlotte, North Carolina.
2 months ago businesswire.com
Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
TOKYO--(BUSINESS WIRE)--Asahi Kasei(TOKYO:3407), a diversified global company, has developed a novel pre-doping technology for high-voltage lithium-ion batteries (LIBs) with silicon-based anodes.…
2 months ago businesswire.com
Asahi Kasei's Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
TOKYO--(BUSINESS WIRE)--Asahi Kasei's project to build new facilities for electrolysis equipment has been awarded key regional economic incentives.
2 months ago businesswire.com
Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte™ Novel Electrolyte in China
TOKYO--(BUSINESS WIRE)--HighChem Shanghai to produce Acetolyte™ for sale to battery manufacturers in China.
4 months ago businesswire.com
Asahi Kasei's Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time
TOKYO--(BUSINESS WIRE)--Peptistar has integrated Asahi Kasei's novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of APIs.
5 months ago businesswire.com
Asahi Kasei Develops Novel Photosensitive Polyimide Film for Advanced Panel-Level Semiconductor Packaging
TOKYO--(BUSINESS WIRE)--Asahi Kasei has combined the features of its photosensitive polyimide (PSPI) and dry film photoresist (DFR) into a new photosensitive film.
5 months ago businesswire.com
Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030
TOKYO--(BUSINESS WIRE)--Asahi Kasei, a diversified global company, has announced plans to streamline operations at its Mizushima Works by fiscal 2030.
6 months ago businesswire.com
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
TOKYO--(BUSINESS WIRE)--Asahi Kasei has announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris).
7 months ago businesswire.com
Chevron Technology Ventures, Asahi Kasei Invest in Heavy-Industry Robotics Company KEWAZO
MUNICH & HOUSTON--(BUSINESS WIRE)--KEWAZO, the robotics company transforming heavy industry worldwide, today announced a new funding round backed by Chevron Technology Ventures, Asahi Kasei, Benson…
7 months ago businesswire.com
Asahi Kasei Begins Installation of Containerized Alkaline-Water Electrolyzer at Finland's First Commercial Hydrogen Refueling Station
TOKYO--(BUSINESS WIRE)--Asahi Kasei has started the installation of an Aqualyzer™-C3 at Finland's first commercial hydrogen refueling station in Jyväskylä.
8 months ago businesswire.com
Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris
CHELMSFORD, Mass. & TOKYO--(BUSINESS WIRE)--Asahi Kasei announced it has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG.
8 months ago businesswire.com
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma announced an exclusive global license agreement regarding novel lead compounds for a single target with Alchemedicine.
8 months ago businesswire.com
Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma in collaboration with Alchemedicine has announced that AK1960 has advanced to a Phase I clinical study.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
7 years ago benzinga.com
Stocks That Broke Yearly Lows Tuesday Morning
Stocks That Broke Yearly Lows Tuesday Morning